Read More Pharma Industry News Why targeting ERK and NF-κB pathways may change Parkinson’s disease drug development Discover how BioVie Inc. is targeting ERK and NF-κB pathways in Parkinson’s disease and what Phase 2 data could mean. Read the full analysis. bySoujanya RaviApril 29, 2026